Letrozol Pharmacare

Letrozole, the active ingredient in Letrozol Pharmacare, is a aromatase inhibitor presented as an oral tablet for oral use. It is indicated for estrogen receptor‑positive breast cancer in postmenopausal women, including adjuvant and metastatic settings.\n\nGNH India supplies Letrozol Pharmacare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozol Pharmacare is an aromatase inhibitor used in the management of hormone‑dependent breast cancer.\n\nEstrogen receptor‑positive breast cancer in postmenopausal women: reduces tumor growth and disease progression.\nAdjuvant treatment of early‑stage breast cancer: lowers risk of recurrence after surgery.\nMetastatic breast cancer: helps control disease spread and symptom burden.

Letrozol Pharmacare may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Hot flashes\n- Joint and muscle pain\n- Nausea or vomiting\n- Fatigue\n- Headache\n- Increased sweating\n\nSerious or Rare Side Effects:\n- Severe liver injury\n- Osteoporotic fractures\n- Deep vein thrombosis or pulmonary embolism\n- Cardiovascular events such as myocardial infarction\n- Hypercholesterolemia\n- Severe allergic reactions (anaphylaxis).

Before initiating therapy, clinicians should consider several safety measures.\n\nMonitor bone health: assess osteoporosis risk and consider calcium/vitamin D supplementation.\nAssess liver function: obtain baseline enzymes and repeat periodically.\nCheck cardiovascular status: evaluate for hypertension or thromboembolic risk.\nAvoid use in pregnancy: contraindicated due to teratogenic potential.\nStore at ambient temperature: keep below 25°C in the original container, protect from moisture.

Letrozol Pharmacare can interact with other medicines, requiring careful management.\n\nMajor Interactions (Avoid):\n- Strong CYP2C19 inhibitors: may increase letrozole exposure.\n- Estrogen‑containing hormonal therapies: antagonize therapeutic effect.\n\nModerate Interactions (Monitor Closely):\n- Anticoagulants (e.g., warfarin): may alter INR values.\n- Tamoxifen: combined use can reduce efficacy of both agents.\n- CYP3A4 inducers (e.g., rifampin): may decrease letrozole plasma levels.